Table 2.
Laboratory data of 302 patients on MHD
| Characteristic | Without PH or HVC (n = 138) | With PH or HVC (n = 121) | With PH and HVC (n = 43) |
|---|---|---|---|
| URR, % | 71.7±8.7 | 69.4±8.1a | 68.1±8.0a |
| Kt/V | 1.7±0.3 | 1.6±0.3a | 1.5±0.3a |
| Albumin, g/L | 30.5±4.2 | 30.2±3.5 | 31.6±3.5 |
| Hemoglobin, g/L | 95.7±22.3 | 101.1±20.8 | 98.7±23.0 |
| Ferritin, ng/mL | 239.1 (88.0–579.7) | 285.8 (83.8–617.3) | 425.3 (145.5–746.0) |
| TSAT, % | 28.9±17.6 | 27.1±17.5 | 27.7±21.1 |
| Ca, mmol/L | 2.4±0.2 | 2.4±0.2 | 2.5±0.2 |
| Phosphorus, mmol/L | 2.1±0.7 | 2.1±0.9 | 2.2±0.9 |
| Calcium-phosphorus product, mg2/dL2 | 59.4±22.0 | 61.8±23.2 | 64.8±24.5 |
| PTH, pg/mL | 193.6 (86.7–406.4) | 231.4 (109.5–576.2) | 278.2 (69.1–499.0) |
| ALP, U/L | 60.0 (50.0–80.5) | 79.0 (56.1–97.5) | 61.5 (55.5–97.5) |
| β2-MG, mg/L | 36.7±13.9 | 40.7±15.2 | 38.3±11.5 |
| CRP, mg/L | 3.2 (1.5–7.0) | 5.8 (2.3–11.9) | 7.4 (1.7–13.6) |
| Uric acid, mmol/L | 431.3±113.3 | 438.4±96.2 | 414.5±88.6 |
| Cholesterol, mmol/L | 4.3±1.1 | 4.2±1.1 | 3.9±1.0 |
| Triglyceride, mmol/L | 1.5±1.2 | 1.4±1.2 | 1.2±0.7 |
| HDL-C, mmol/L | 1.1±0.4 | 1.1±0.4 | 1.0±0.3 |
| LDL-C, mmol/L | 2.2±0.9 | 2.2±0.8 | 2.1±0.8 |
Data are given as mean ± SD, medians (25th to 75th percentiles), or numbers and percentages as appropriate.
URR, urea reduction ratio; Kt/V, dialyzer clearance of urea × time/volume; TSAT, transferrin saturation; PTH, transferrin saturation; ALP, alkaline phosphatase; β2-MG, beta-2 macroglobulin; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
a p < 0.05 compared to 0-risk factor group.